Key regions: France, Brazil, South Korea, India, China
The global antiviral drugs market has been experiencing significant growth in recent years, and Brazil is no exception.
Customer preferences: Brazil has a large population of individuals living with HIV/AIDS, which has been a significant driver of the antiviral drugs market. Additionally, the country has experienced outbreaks of dengue fever, Zika virus, and other infectious diseases, leading to a higher demand for antiviral drugs.
Trends in the market: Brazil's antiviral drugs market has been experiencing growth due to the increasing prevalence of infectious diseases and the growing demand for antiviral drugs. The market has also seen an increase in research and development efforts, leading to the introduction of new drugs and treatments. The market has also seen a shift towards generic antiviral drugs, as they are more affordable and accessible to the general population.
Local special circumstances: Brazil has a universal healthcare system that provides free access to antiviral drugs for individuals living with HIV/AIDS. This has been a significant factor in driving demand for antiviral drugs in the country. Additionally, the Brazilian government has implemented various public health initiatives to combat the spread of infectious diseases, leading to a higher demand for antiviral drugs.
Underlying macroeconomic factors: Brazil's antiviral drugs market has been influenced by various macroeconomic factors, including the country's GDP growth, healthcare spending, and regulatory environment. The Brazilian government has been investing heavily in its healthcare system, leading to increased access to antiviral drugs. Additionally, the government has implemented policies to encourage local production of antiviral drugs, leading to a more competitive market. However, the market has also been impacted by the country's economic instability, which has led to fluctuations in demand for antiviral drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
